Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

SABCS 2022

6 - 10 Dec 2022
Henry B. Gonzalez Convention Center, San Antonio, United States of America
Videos
News
Breast-conserving therapy may be option for multiple breast lesions
Dr Judy Boughey - Mayo Clinic, Rochester, USA
Breast-conserving therapy may be option for multiple breast lesions ( Dr Judy Boughey - Mayo Clinic, Rochester, USA )
13 Jan 2023
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...
Dr Ian Krop - Yale Cancer Center, Connecticut, USA
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )
23 Dec 2022
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy...
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
22 Dec 2022
Comment: POLAR gene profile can identify which patients can safely avoid...
Prof Christos Markopoulos- National and Kapodistrian University of Athens...
Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery ( Prof Christos Markopoulos- National and Kapodistrian University of Athens, Athens, Greece )
22 Dec 2022
Updates from TAILORx and RxPONDER: Implications for practice
Prof Christos Markopoulos and Dr Kevin Kalinsky
Updates from TAILORx and RxPONDER: Implications for practice ( Prof Christos Markopoulos and Dr Kevin Kalinsky )
21 Dec 2022
Interruption of endocrine therapy in young breast cancer patients does not...
Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA
Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse ( Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA )
21 Dec 2022
Genetic profiling identifies patients who can omit radiation therapy after...
Prof Per Karlsson - Sahlgrenska Comprehensive Cancer Centre, Gothenburg, Sweden
Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery ( Prof Per Karlsson - Sahlgrenska Comprehensive Cancer Centre, Gothenburg, Sweden )
21 Dec 2022
A genomic assay may predict long-term prognosis in premenopausal patients with...
Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022
Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...
Dr Sara Hurvitz - University of California, Los Angeles, USA
Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )
15 Dec 2022
Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...
Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA
Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )
14 Dec 2022
Camizestrant may be superior to fulvestrant in patients with hormone receptor...
Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain
Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )
14 Dec 2022
Opinion: Premature regulatory approval by the FDA
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Opinion: Premature regulatory approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
13 Dec 2022
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...
Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )
12 Dec 2022
HER2DX confirms the ability of the test to predict long-term survival and...
Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain
HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )
9 Dec 2022
Treatment decision guided by CTC count may improve long-term outcomes for mBC
Prof Jean-Yves Pierga - Institut Curie, Paris, France
Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )
9 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation